About 100 reports

  • PERCENTAGE OF PATIENTS WITH HIV-1 RNA LEVELS <50 COPIES/ML FROM THE SMARTMRK STUDY
  • EFFICACY OF ATRIPLA COMPARED WITH COMBIVIR + SUSTIVA

AMONG TREATMENT-NAÏVE SUBJECTS, THE VIROLOGIC RESPONSE RATE AT ## WEEKS WAS ##% IN SUBJECTS WITH BASELINE HIV-## RNA ##, ## OR MORE COPIES/ ML, AND ##% IN THOSE WITH BASELINE HIV-## RNA UNDER ##, ## COPIES/ ML.

  • HIV AIDS
  • East Asia
  • Gilead Sciences, Inc.
  • Merck & Co., Inc.
  • ViiV Healthcare Ltd.
  • MARKET OUTLINE
  • MARKET DRIVERS

In NAT, a region of viral DNA or RNA is targeted and amplified, enabling the detection of infected blood samples.

  • HIV AIDS
  • HIV Antiviral
  • Gilead Sciences, Inc.
  • Janssen Biotech, Inc.
  • ViiV Healthcare Ltd.
  • Indication
  • RHEONIX INC, RECENT DEVELOPMENTS

Testing often involves two separate steps: one to detect a pathogen' s nucleic acids (RNA or DNA) and another to test for antibodies, the proteins the body produces in response to pathogens.

  • Biotech Diagnostics
  • HIV AIDS
  • United States
  • World
  • Rheonix, Inc.

The revenue in 2017 decreased by approximately ##%, as compared to 2016.

  • HIV AIDS
  • Therapy
  • World
  • Market Size
  • Merck & Co., Inc.
  • LIFECYCLE OF HIV
  • CLASSES OF DRUGS WITH THEIR FUNCTIONS

Those HIV proteins along with RNA form the mature and infectious virus. ##.

  • HIV AIDS
  • World
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • APR 05, 2017: NIDA ANNOUNCES RECIPIENTS OF 2017 AVANT-GARDE AWARDS FOR HIV/AIDS RESEARCH

Poeschla will use animal and human cells to explore the use of viral RNA-dependent RNA polymerase (RdRP) to enhance broad-spectrum (innate) immunity against various viruses, including HIV-##.

  • HIV AIDS
  • Opioid
  • United States
  • Lightlake Therapeutics Inc.
  • Opiant Pharmaceuticals, Inc.

You can easily book an appointment with one online.

  • HIV AIDS
  • World
  • Forecast
  • Millipore Corporation
  • Thermo Fisher Scientific, Inc.

" There is likely a good reason why genes that make RNAs rather than proteins exist.

  • Cancer
  • HIV AIDS
  • Medical Biotechnology
  • Therapy
  • United States

STRENGTH: ## LOW; ## HIGH F.

  • HIV AIDS
  • Bristol-Myers Squibb Company
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • ViiV Healthcare Ltd.
  • 2.4.2 Forecast Assumptions and Methods

Available Trends; ##(##): ##-##.

  • HIV AIDS
  • East Asia
  • Japan
  • Forecast
  • UNAIDS
  • Vendor landscape
  • Market drivers

Some of its products include HIV ##/ ## STAT-PAK, HIV ##/ ## STAT-PAK DIPSTICK, and STAT-VIEWTM HIV ##/ ##.

  • HIV AIDS
  • World
  • Alere Inc.
  • DiaSorin S.p.A.
  • Roche Group

SOU HIV-## RNA, HCV RNA, HBV DNA, AND WEST NILE VIRUS (WNV) RNA.

  • HIV AIDS
  • China
  • Abbott Laboratories, Inc.
  • Immucor, Inc.
  • Roche Group
  • syphilis Treponema Pallidum Haemagglutination
  • Hepatitis C Virus (HCV)

Commonly used NAT assays detect HIV-## RNA, HCV RNA, HBV DNA, and West Nile Virus (WNV) RNA.

  • HIV AIDS
  • United States
  • Grifols, S.A.
  • Hologic, Inc.
  • Immucor, Inc.

The company has also signed a deal worth $## billion with Moderna for its messenger RNA therapeutics platform in developing new antiviral vaccines and passive immunity therapies.

  • HIV AIDS
  • Bristol-Myers Squibb Company
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Johnson & Johnson

HIV

4385 5000 3900
  • Stribild pivotal trial data in HIV-1 infection
  • Isentress pivotal trial data in HIV-1 infection

Mellors JW, Margolick JB, Phair JP, Rinaldo CR, Detels R, Jacobson LP, Muñoz A (2007) Prognostic value of HIV-## RNA, CD## cell count, and CD## Cell count slope for progression to AIDS and death in untreated HIV-## infection.

  • HIV AIDS
  • Europe
  • European Union
  • North America
  • United States
  • VIRAL INFECTIONS THERAPEUTICS MARKET, MAJOR MARKETS, HIV PREVALENCE ('000),
  • Executive Summary

DYNAMICS OF HCV RNA-DEPENDENT RNA POLYMERASE NS##B IN COMPLEX WITH RNA.

  • HIV AIDS
  • Infectious Disease
  • Therapy
  • Market Size
  • Gilead Sciences, Inc.
  • THAN ONE HIV-1 RNA COPY/ML BLOOD AND TWO PATIENTS HAD LESS THAN 4 COPIES/ML.
  • JUL 16, 2018: CYTODYN ANNOUNCES POSITIVE RESULTS FROM COMPLETED PIVOTAL PRO 140 HIV COMBINATION TRIAL

The primary endpoint was the proportion of participants with greater than ##. ##log reduction in HIV-## RNA viral load from baseline at the end of the one-week treatment period.

  • HIV AIDS
  • Pharmaceutical
  • United States
  • Product Initiative
  • CytoDyn Inc.
  • Nov 19, 2018: Yale team creates new tool for studying elusive elements of human genome

Researchers can silence the proteins with small interfering RNA (siRNA), a doublestranded RNA that hinders the expression of targeted genes.

  • HIV AIDS
  • Pharmaceutical
  • Therapy
  • United States
  • Patrys Limited
  • AG-1105 - DRUG PROFILE

The primary outcome measures of study is the HIV-## ##-Jun-2016 ##-Nov-2013 PHASE I - TRIAL DETAILS RNA Change from Baseline.

  • HIV AIDS
  • Medical Biotechnology
  • United States
  • World
  • CytoDyn Inc.
  • EOSCAPE-HIV RNA PLUS
  • EOSCAPE HIV-1 RNA VIRAL LOAD TEST

Wave ## provides EOSCAPE-HIV, an in vitro nucleic acid assay, which enables the detection and quantitation of human immunodeficiency virus type ## (HIV-##) RNA.

  • Hepatitis
  • HIV AIDS
  • United States
  • Company
  • Product Initiative
  • SAMBA - HIV-1 VIRAL LOAD ASSAY - PRODUCT DESCRIPTION
  • TRUENAT HIV VIRAL LOAD ASSAY - PRODUCT STATUS

Wave ## provides EOSCAPE-HIV, an in vitro nucleic acid assay, which enables the detection and quantitation of human immunodeficiency virus type ## (HIV-##) RNA.

  • Clinical Trial
  • HIV AIDS
  • Therapy
  • United States
  • Quidel Corporation

The company operates under one business segment.

  • HIV AIDS
  • North America
  • United States
  • Forecast
  • Merck & Co., Inc.
  • CLINICAL TRIAL PROFILE SNAPSHOTS

Avium Complex (MAC) Lung Disease GDCT## NCT##, ## Infectious Disease Lung Disease, Mycobacterium avium Infections Completed Phase IV Interventional clarithromycin; rifabutin University of Texas Health Science Center at Tyler Abbott Laboratories ## Aug 1995 ## Aug 2002 ## ## ##

  • Anti-Infective
  • HIV AIDS
  • World
  • Product Initiative
  • Pfizer Inc.

The prominent features of this report are - ##.

  • Clinical Trial
  • HIV AIDS
  • Monoclonal Antibody
  • Pharmaceutical
  • World
  • TRANSFER MEMBRANE MARKET FOR NORTHERN BLOTTING, BY REGION, 2016-2023 (USD MILLION)

The major steps involved in northern blotting are RNA isolation, probe generation, gel electrophoresis, transfer of RNA to transfer membrane and immobilization, hybridization with probe, washing, and detection.

  • Biotechnology
  • HIV AIDS
  • Proteomics
  • Forecast
  • Merck & Co., Inc.
  • Glycoprotein 41 (gp41) - Product Development Milestones
  • Glycoprotein 41 (gp41) - Drug Profiles

At week ##, the decline of HIV-## RNA from baseline was ##. ## (##. ##-##. ##) log## and ##. ## (##. ##-##. ##) log## copies/ ml, and suppression of HIV-## RNA to below ## copies/ ml was achieved in ##. ## percent (##/ ##) and ##. ## percent (##/ ##) patients, for the

  • HIV AIDS
  • Pharmaceutical
  • United States
  • Product Initiative
  • Mymetics Corporation

Pringle served as Chairman of the Board and Director of one of the Company' s predecessors, Epitope, Inc.

  • HIV AIDS
  • United States
  • Company Financials
  • Demand
  • OraSure Technologies, Inc.
  • 06/09/2018: WEEKLY INJECTIONS OF CYTODYNS PRO 140 IN COMBINATION WITH OPTIMIZED ANTIRETROVIRAL TREATMENT SHOWS LONG-ACTING HIV-1 VIRAL SUPPRESSION
  • 02/20/2018: CYTODYN REPORTS PRIMARY ENDPOINT ACHIEVED IN PRO 140 PIVOTAL COMBINATION THERAPY TRIAL IN HIV INFECTION

The trial' s primary endpoint was the proportion of participants with greater than ##. ##log reduction in HIV-## RNA viral load from baseline at the end of the one-week treatment period.

  • HIV AIDS
  • Medical Biotechnology
  • United States
  • Company
  • CytoDyn Inc.

The prominent features of this report are - ##.

  • Cancer
  • Clinical Trial
  • HIV AIDS
  • Oncology
  • Merck & Co., Inc.
  • Feb 02, 2017: Phase I Clinical Data of ABX464, ABIVAX's First-in-Class anti-HIV Drug, Published in Two Articles in Peer-Reviewed Journals
  • Apr 04, 2017: ABIVAX initiates clinical trial (ABX464-005) to evaluate the effect of ABX464 on HIV-reservoirs in HIV Patients

Long lasting control of viral rebound with a new drug ABX## targeting Rev - mediated viral RNA biogenesis.

  • HIV AIDS
  • Infectious Disease
  • France
  • Company
  • ABIVAX